Xenon Pharmaceuticals annual operating margin
2012
2013
2014
2015
2016
2017
2019
2020
2021
2022
2025
Xenon Pharmaceuticals Operating Margin Growth & History (XENE)
Xenon Pharmaceuticals's operating margin was −4,974.27% for fiscal 2025.
View full Xenon Pharmaceuticals company overviewXenon Pharmaceuticals annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −4,974.27% | — |
| 2022 | 2022-12-31 | −1,368.91% | −940.46 pp |
| 2021 | 2021-12-31 | −428.45% | −331.14 pp |
| 2020 | 2020-12-31 | −97.31% | +529.71 pp |
| 2019 | 2019-12-31 | −627.02% | — |
| 2017 | 2017-12-31 | −10,474.28% | −9097.85 pp |
| 2016 | 2016-12-31 | −1,376.43% | −1316.33 pp |
| 2015 | 2015-12-31 | −60.10% | −99.24 pp |
| 2014 | 2014-12-31 | 39.15% | +3.64 pp |
| 2013 | 2013-12-31 | 35.50% | +57.54 pp |
| 2012 | 2012-12-31 | −22.04% | — |
Xenon Pharmaceuticals quarterly operating margin
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q1.25
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q1 2025 | 2025-03-31 | −969.84% | — |
| Q3 2022 | 2022-09-30 | −28,884.85% | −28692.85 pp |
| Q2 2022 | 2022-06-30 | −5,655.78% | −4641.45 pp |
| Q1 2022 | 2022-03-31 | −198.14% | +170.35 pp |
| Q4 2021 | 2021-12-31 | −664.65% | −413.72 pp |
| Q3 2021 | 2021-09-30 | −192.00% | −44.01 pp |
| Q2 2021 | 2021-06-30 | −1,014.34% | −1009.51 pp |
| Q1 2021 | 2021-03-31 | −368.49% | −255.00 pp |
| Q4 2020 | 2020-12-31 | −250.93% | — |
| Q3 2020 | 2020-09-30 | −147.99% | +107.76 pp |
| Q2 2020 | 2020-06-30 | −4.83% | — |
| Q1 2020 | 2020-03-31 | −113.49% | — |
| Q3 2019 | 2019-09-30 | −255.74% | — |
| Q4 2017 | 2017-12-31 | −50,318.75% | −48866.09 pp |
| Q3 2017 | 2017-09-30 | −3,274.24% | −1499.18 pp |
| Q2 2017 | 2017-06-30 | −52,620.00% | −51078.60 pp |
| Q1 2017 | 2017-03-31 | −49,918.75% | −48977.32 pp |
| Q4 2016 | 2016-12-31 | −1,452.66% | −1372.00 pp |
| Q3 2016 | 2016-09-30 | −1,775.06% | −1755.96 pp |
| Q2 2016 | 2016-06-30 | −1,541.40% | −1546.32 pp |
| Q1 2016 | 2016-03-31 | −941.43% | −788.39 pp |
| Q4 2015 | 2015-12-31 | −80.66% | −81.38 pp |
| Q3 2015 | 2015-09-30 | −19.10% | −84.74 pp |
| Q2 2015 | 2015-06-30 | 4.92% | −21.09 pp |
| Q1 2015 | 2015-03-31 | −153.04% | −173.68 pp |
| Q4 2014 | 2014-12-31 | 0.72% | −35.45 pp |
| Q3 2014 | 2014-09-30 | 65.65% | +5.22 pp |
| Q2 2014 | 2014-06-30 | 26.01% | +39.76 pp |
| Q1 2014 | 2014-03-31 | 20.64% | −15.46 pp |
| Q4 2013 | 2013-12-31 | 36.16% | — |
| Q3 2013 | 2013-09-30 | 60.43% | — |
| Q2 2013 | 2013-06-30 | −13.75% | — |
| Q1 2013 | 2013-03-31 | 36.10% | — |
Xenon Pharmaceuticals operating margin trends
Over the last five fiscal years, Xenon Pharmaceuticals's operating margin decreased from −97.31% to −4,974.27%, a change of −4876.96 percentage points. The latest reported quarter, Q1 2025, shows −969.84%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xenon Pharmaceuticals source filings ↗Community posts
Xenon files its seizure-drug application while pausing new psychiatry enrollment
Xenon ($XENE) submitted a US new-drug application for azetukalner to treat focal seizures, supported by its X-TOLE and X-TOLE2 studies and more than 1,500 patient-years of exposure. Submission is an application milestone, not confirmation t ...
